Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study.

Sakiko TeruiMari IgariTakahiro TsunoTomoko OkuyamaRyota InoueMayu KyoharaYasuo TerauchiJun Shirakawa

Published in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2024)

Switching from a DPP4 inhibitor to low-dose (0.3 mg) liraglutide once daily significantly reduced the blood glucose levels and excursions of the blood glucose levels even from the very day after the treatment switch, with no serious adverse events.

Keyphrases

blood glucose
low dose
glycemic control
high dose
blood pressure
type diabetes
physical activity
adipose tissue
metabolic syndrome
weight loss
skeletal muscle